Zymeworks Inc.
Zymeworks Inc. (Nasdaq: ZYME) is a biotechnology company that develops antibody-based therapeutics and manages a portfolio of licensed healthcare assets, targeting difficult-to-treat cancers, inflammatory conditions and autoimmune diseases. Its proprietary platforms support multispecific antibodies and antibody-drug… From the company’s description.
Over the twelve months to Jun 30, 2026, Zymeworks Inc. reported revenue of $37.13M, down 69.8% from a year earlier, and a net loss of $149.99M. Its operating margin was −419.0%, and operations used $119.34M in cash. In fiscal 2025, it reported revenue of $105.97M, up 38.9% from fiscal 2024, and a net loss of $81.13M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Zymeworks Inc. does
In the company’s own words
Zymeworks Inc. (Nasdaq: ZYME) is a biotechnology company that develops antibody-based therapeutics and manages a portfolio of licensed healthcare assets, targeting difficult-to-treat cancers, inflammatory conditions and autoimmune diseases. Its proprietary platforms support multispecific antibodies and antibody-drug conjugates, while strategic partnerships share development and commercialization responsibilities and provide potential milestone and royalty income. Zymeworks has one operating segment and reports its business as a single segment. Its partnered programs include Ziihera (zanidatamab), approved for HER2-positive biliary tract cancer in multiple jurisdictions, and pasritamig, which partners are evaluating in prostate cancer. Its wholly owned pipeline includes clinical-stage ADC candidates ZW191 and ZW251, along with programs in multispecific antibodies and autoimmune and inflammatory disease. The company’s platform brands include Azymetric, EFECT, ProTECT and ZymeLink. For fiscal 2025, Zymeworks earned $69.9 million in milestone payments, an option exercise fee and a research-period extension fee from collaboration partners. Its website is www.zymeworks.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- MIDDLETOWN, DE
- Fiscal year end
- December
- CIK
- 1937653
- SIC
- 2834
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Zymeworks Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Zymeworks Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Zymeworks Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Zymeworks Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Zymeworks Inc.'s last four quarterly filings that the numbers alone won't show?”